Ship operations are followed carefully with smart solutions, IoT and AI, although different segments of the industry have reached different degrees of adoption.

The areas where they are most developed are in safety, navigation and avoiding human errors.When it comes to hotel areas, we see most progress in the service and maintenance operations.

Besides from operational smart solutions, the technology could be used for automating some parts of the sales, engineering, and construction processes as well, minimizing human errors, improving service, and ensuring time schedules are kept.“Our company has come far in the development of smart solutions for ships, especially in catering operations, and we have seen that the best results are achieved when the systems are developed together with the customer, considering their needs and degree of digital maturity,” says Björn Stenwall, President & CEO of ALMACO Group.Björn is respected and well-known in the maritime community with a total of 30+ years of experience in the industry.

His roots come from MacGregor where he was in charge of its Global Service Division, after which he was headhunted by ALMACO to run the Catering Division and hold the COO position on Group level.

This year in January, Björn was appointed President & CEO of the company.Enabling ‘Turnkey’ SolutionsALMACO is a full turnkey provider of all hotel, and catering areas including laundries in the marine and offshore industry.

Its motto is to manage large-scale full turnkey projects and make it look easy.

To order this 170+ page report, please visit this link Key InclusionsA detailed review of the overall landscape of fragment-based drug discovery library and service providers along with the information on type of product (library and technology), type of service offered (fragment screening and fragment optimization), type of technique used (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and other screening techniques), other services offered (target identification / validation, hit identification, hit-to-lead / lead generation, lead optimization), and end user (industry, academia, and contract research organizations).Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered).

Each profile features a brief overview of the company, its financial information (if available), fragment-based library and service portfolio, information on other drug discovery services, recent developments and an informed future outlook.An analysis of the partnerships that have been established in the recent past, covering R collaborations, mergers and acquisitions, product development and commercialization agreements, commercialization agreements, distribution and supply agreements, product integration agreements, service agreements, and other relevant types of deals.A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.An insightful competitiveness analysis of fragment-based drug discovery library and service providers, based on supplier power (based on the years of experience of service provider) and key specifications, such as number of fragment libraries and number of screening techniques.An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.Informed estimates of the existing market size and the future opportunity for fragment-based drug discovery library and services, over the next decade.

Based on multiple parameters, such as annual number of drug discovery projects, outsourcing profile, and adoption of fragment-based drug discovery approach, we have provided informed estimates on the evolution of the market for the period 2020-2030.

The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Type of Screening Technique UsedX-ray CrystallographyNuclear Magnetic ResonanceSurface Plasmon ResonanceOther Screening Techniques Type of Service OfferedLibrary ScreeningFragment ScreeningFragment Optimization End UserIndustry PlayersNon-Industry Players Key geographical regionsPress Release: Variation 4 (Format 5) North America (US and Canada)Europe (UK, France, Germany, Spain, Italy, and rest of Europe)Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world) The report also features inputs from eminent industry stakeholders, according to whom the fragment-based approach significantly simplifies the drug discovery process.

The report includes detailed transcripts of discussions held with the following experts:Jean-Yves Ortholand (Co-founder and Chief Executive Officer, Edelris)Björn Walse (Chief Executive Officer, SARomics Biostructures) To request sample pages, please visit this link                                                                                                                             Key Questions AnsweredWho are the leading players in the fragment-based drug discovery library and services market?What are the key biophysical techniques used by service providers for screening fragment libraries and lead optimization?Which types of partnership models are commonly adopted by stakeholders in this domain?What is the likely cost-saving opportunity associated with the use of fragment-based drug discovery?How is the current and future market opportunity likely to be distributed across key market segments?

You may also be interested in the following titles:DNA-Encoded Libraries: Platforms and Services MarketAntibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches) Contact Us:Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 [email protected]

To order this 170+ page report, which features 55+ figures and 80+ tables, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html Key Market Insights Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologiesIndustry stakeholders offer either customized fragment libraries or proprietary screening technologies, a select few claim to provide both; however, the expertise related to fragment optimization is still limited in this domainMajority of stakeholders in the competitive market landscape are small / mid-sized firms, offering a variety of services to cater to the needs of a diverse clientele, featuring industry and non-industry playersStakeholders are actively expanding their capabilities in order to enhance their respective fragment-based drug discovery service portfolios and thereby, maintain a competitive edge in this upcoming industryThe rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on drug discovery for diverse range of indicationsConsidering the prevalent trend of drug discovery and approval, we are led to believe that the fragment-based approach has the potential to enable significant time and cost savingsThe market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various types of screening techniques, services and geographies For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html                                                                                                               Table of Contents  PREFACE1.1.

Chapter Outlines  EXECUTIVE SUMMARY  INTRODUCTION3.1.

Fragment-based Drug Discovery (FBDD)Press Release: Variation 2 (Format 3) 3.5.1.

Concluding Remarks  COMPANY COMPETITIVENESS ANALYSIS8.1.

Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific  COST SAVING ANALYSIS9.1.

Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-203010.4.3.

To order this 170+ page report, which features 55+ figures and 80+ tables, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html Key Market Insights Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologiesIndustry stakeholders offer either customized fragment libraries or proprietary screening technologies, a select few claim to provide both; however, the expertise related to fragment optimization is still limited in this domainMajority of stakeholders in the competitive market landscape are small / mid-sized firms, offering a variety of services to cater to the needs of a diverse clientele, featuring industry and non-industry playersStakeholders are actively expanding their capabilities in order to enhance their respective fragment-based drug discovery service portfolios and thereby, maintain a competitive edge in this upcoming industryThe rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on drug discovery for diverse range of indicationsConsidering the prevalent trend of drug discovery and approval, we are led to believe that the fragment-based approach has the potential to enable significant time and cost savingsThe market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various types of screening techniques, services and geographies For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html                                                                                                               Table of Contents  PREFACE1.1.

Chapter Outlines  EXECUTIVE SUMMARY  INTRODUCTION3.1.

Fragment-based Drug Discovery (FBDD)Press Release: Variation 2 (Format 3) 3.5.1.

Concluding Remarks  COMPANY COMPETITIVENESS ANALYSIS8.1.

Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific  COST SAVING ANALYSIS9.1.

Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-203010.4.3.

To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this link Key Market Insights Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologiesIndustry stakeholders offer either customized fragment libraries or proprietary screening technologies, a select few claim to provide both; however, the expertise related to fragment optimization is still limited in this domainMajority of stakeholders in the competitive market landscape are small / mid-sized firms, offering a variety of services to cater to the needs of a diverse clientele, featuring industry and non-industry playersStakeholders are actively expanding their capabilities in order to enhance their respective fragment-based drug discovery service portfolios and thereby, maintain a competitive edge in this upcoming industryThe rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on drug discovery for diverse range of indicationsConsidering the prevalent trend of drug discovery and approval, we are led to believe that the fragment-based approach has the potential to enable significant time and cost savingsThe market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various types of screening techniques, services and geographies For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html                                                                                                               Table of Contents  PREFACE1.1.

Chapter Outlines  EXECUTIVE SUMMARY  INTRODUCTION3.1.

Fragment-based Drug Discovery (FBDD)Press Release: Variation 2 (Format 3) 3.5.1.

Concluding Remarks  COMPANY COMPETITIVENESS ANALYSIS8.1.

Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific  COST SAVING ANALYSIS9.1.

Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-203010.4.3.